Latest Japan News

Memphasys has inked its first exclusive commercialization agreement in South-East Asia with TMSC Vietnam, targeting the fast-growing Vietnamese IVF sector with its Felix™ sperm separation system. The two-year contract, valued at A$530,000, hinges on regulatory approval expected by August 2026.

Tivan has produced 195 kg of acidgrade fluorspar at 98.6% CaF2 from its Speewah mini-pilot, exceeding the 97% market standard and setting the stage for a full pilot and offtake negotiations.

Amplia Therapeutics reported encouraging mature data from its ACCENT pancreatic cancer trial showing improved survival and response rates with narmafotinib. The company raised $27.5 million to fund development and manufacturing scale-up, while discontinuing a parallel trial due to chemotherapy toxicity.

X2M Connect has secured $1.49 million in its second tranche placement and plans to issue additional options to investors, pending shareholder approval, to support its expanding smart city technology ambitions.

Neuren Pharmaceuticals reported a 15% rise in 2025 royalties from DAYBUE®, boosted by strong US sales and a new powder formulation launch. The company is progressing its pivotal Phase 3 trial for NNZ-2591 in Phelan-McDermid syndrome and reassessing capital management amid solid cash reserves.

XReality Group (ASX:XRG) posts strong FY26 revenue and ARR growth, marking key milestones with its first commercial MR-1 mixed reality sale to the US Department of Defense and debut European contract with the Swedish Armed Forces.

Nufarm Limited posted a 35% rise in underlying net profit after tax to $52.1 million for HY26, driven by margin expansion and cost discipline despite a 5% revenue decline to $1.71 billion. The company confirmed its FY26 outlook, targeting strong earnings growth and leverage reduction.

Bio-Gene Technology has raised A$3.21 million to complete critical safety studies for its novel insecticide Flavocide and ramp up production of its natural insecticide Qcide, advancing its path to commercialisation in multiple global markets.

Mont Royal Resources has identified significant high-grade fluorspar mineralisation up to 39.8% CaF2 at its Mallard Prospect, located just 1.4km from the flagship Ashram Deposit in Québec. The discovery highlights expanding fluorspar potential amid tightening global markets and China's shift to net importer status.

Guzman y Gomez has abruptly exited the US market, citing financial underperformance despite brand progress, while reaffirming strong Australian growth and international franchise confidence.

AFT Pharmaceuticals posted a 22% revenue jump to NZ$254.7 million and a 39% increase in operating profit to a record NZ$24.4 million for FY26, exceeding guidance. The company targets over NZ$300 million revenue for FY27, fueled by international expansion and a deepening R&D pipeline.

Stelar Metals (ASX:SLB) is accelerating exploration at its Hill of Leaders Tungsten Project in the Northern Territory, aiming to capitalise on soaring tungsten prices and critical mineral demand driven by Chinese export restrictions.